CTSA and lupus nephritis: Importantly, targeting GSL biosynthesis may attenuate maladaptive organelle stress responses and protect against glomerular injury and be useful as a co-therapy in conjunction with anti-inflammatory therapeutics for a variety of renal inflammatory diseases, such as lupus nephritis.